Peptides for Wellness & Health Optimization
Peptides are short chains of amino acids (the same fundamental building blocks that make up proteins) but they function in the body in a unique and highly targeted way. Rather than acting as structural components like many larger proteins, peptides typically serve as biological signaling molecules, helping cells communicate and coordinate complex physiological processes.
They play essential roles in regulating metabolism, hormone release, immune responses, inflammation, tissue repair, appetite, sleep, and many other functions. Examples of naturally occurring peptides include insulin, glucagon, growth hormone–releasing peptides, and numerous immune signaling molecules.
Because of their size and structure, peptides occupy a distinct space between traditional small-molecule drugs and larger biologic therapies. This gives them several unique characteristics:
High specificity
Peptides often bind very precisely to receptors, allowing them to influence particular biological pathways with relatively targeted effects.
Powerful physiological impact
Even small changes in peptide signaling can lead to meaningful changes in metabolism, recovery, or hormonal rhythms.
Shorter biological half-lives
Many peptides are rapidly broken down in the body, which can reduce long-term accumulation but may require careful dosing strategies.
Growing therapeutic interest
Advances in biotechnology have made it easier to design and synthesize peptides, leading to increasing exploration of their potential uses in medicine and longevity science.
For these reasons, peptides are often discussed as a category of their own. They represent a class of bioactive molecules that can directly influence regulatory systems within the body.
However, this biological potency also means that peptides are not risk-free.
Peptides are not risk-free. Before considering their use, it is essential to carefully weigh potential benefits against possible risks: side effects, unknown long-term outcomes, dosing challenges, and product purity. Decisions should be based on credible evidence and ideally made in consultation with a qualified healthcare professional.
The table below summarizes commonly discussed peptides, their mechanisms of action, and the current state of evidence.
A Multiple large RCTs
B Strong RCT; optimization off-label
C Small or surrogate-endpoint human trials
D Limited human evidence
E No persuasive human evidence; primarily preclinical
Regulatory note: WADA status reflects the 2026 Prohibited List. For educational purposes only. Always consult a licensed physician.
Incretin & Metabolic Peptides
| Peptide (Brand Names) | Evidence | Indication | Regulatory Status |
|---|
| ▶ | SemaglutideWegovy, Ozempic, Rybelsus | A | Obesity (BMI ≥30 or ≥27 + comorbidity); T2DM; CV risk reduction | FDA-approved 2021 (obesity). EMA Jan 2022. Rx only.WADA: Not prohibited |
| ▶ | TirzepatideZepbound, Mounjaro | A | Obesity; T2DM; obstructive sleep apnea in adults with obesity | FDA-approved 2022 (T2DM), 2023 (obesity), 2024 (OSA). Rx only.WADA: Not prohibited |
| ▶ | LiraglutideSaxenda, Victoza | A | Obesity (BMI ≥30 or ≥27 + comorbidity); T2DM | FDA-approved (Rx). Saxenda label current 2025.WADA: Not prohibited |
| ▶ | ExenatideByetta, Bydureon ER | B | T2DM (not primarily indicated for obesity/wellness) | FDA-approved (Rx). Byetta label current 2025.WADA: Not prohibited |
| ▶ | PramlintideSymlin | B | T2DM and T1DM insulin adjunct; studied for obesity as lifestyle adjunct | FDA-approved (Rx) for diabetes adjunct. Obesity use off-label.WADA: Not prohibited |
Growth Hormone (GH) Axis Peptides
| Peptide (Brand Names) | Evidence | Indication | Regulatory Status |
|---|
| ▶ | TesamorelinEgrifta WR | B | HIV lipodystrophy (excess abdominal fat). NOT indicated for weight loss management | FDA-approved (Rx) for HIV lipodystrophy ONLY.WADA: Prohibited (S2) |
| ▶ | SermorelinGeref (discontinued) | C | Historically: pediatric GH deficiency. Now compounded off-label for anti-aging / body composition | US product withdrawn. Compounded only. Not FDA-approved.WADA: Prohibited (S2) |
| ▶ | CJC-1295CJC-1295 w/ DAC; MOD GRF 1-29 | C | Investigational: GH/IGF-1 axis enhancement, body composition, anti-aging | Not FDA-approved. Higher-risk bulk substance for compounding.WADA: Prohibited (S2) |
| ▶ | IpamorelinIpamorelin | C | Investigational: GH secretagogue. Phase II RCT for postoperative ileus showed NO significant benefit | Not FDA-approved. Bulk substance with potential significant safety risk.WADA: Prohibited (S2) |
| ▶ | GHRP-2Pralmorelin (Japan: diagnostic) | C | Clinical GH stimulation/diagnostic use (Japan approved). Wellness use not clinically validated | Not FDA-approved. Japan approval for diagnostic use only.WADA: Prohibited (S2) |
| ▶ | GHRP-6GHRP-6 | D | Investigational: GH secretagogue. No robust wellness outcomes RCT base | Not FDA-approved. FDA compounding risk flagged.WADA: Prohibited (S2) |
Melanocortin Peptides
| Peptide (Brand Names) | Evidence | Indication | Regulatory Status |
|---|
| ▶ | AfamelanotideScenesse, Melanotan I | B | Erythropoietic protoporphyria (EPP). NOT a tanning drug | FDA-approved for EPP indication only (2019).WADA: Not prohibited |
| ▶ | Melanotan IIMT-II | E | Marketed for tanning/libido. NOT approved anywhere. Serious adverse event case reports | Not FDA-approved. FDA flags significant safety concerns.WADA: Not prohibited |
| ▶ | PT-141 (Bremelanotide)Vyleesi | A | HSDD in premenopausal women. NOT for postmenopausal women, men, or performance enhancement | FDA-approved June 2019 (NDA 210557). Premenopausal HSDD only.WADA: Not prohibited |
Neurobehavioral Peptides
| Peptide (Brand Names) | Evidence | Indication | Regulatory Status |
|---|
| ▶ | OxytocinPitocin, intranasal (off-label) | C | FDA-approved: obstetric indications. Off-label/research: autism social outcomes, anxiety, bonding | FDA-approved for obstetric indications only. Intranasal wellness is off-label/research.WADA: Not prohibited |
| ▶ | DesmopressinNocdurna, DDAVP | B | Nocturia; central diabetes insipidus; nocturnal enuresis. NOT a wellness agent | FDA-approved (Rx). Boxed warning for hyponatremia.WADA: Not prohibited |
| ▶ | DSIPEmideltide, Delta Sleep-Inducing Peptide | D | Investigational: sleep induction, insomnia. Evidence weak and limited | Not FDA-approved. Higher-risk compounding bulk substance.WADA: Not prohibited |
| ▶ | SelankSelank | C | Anxiety, cognitive enhancement (Russia/Ukraine approved). Research compound in Western markets | Approved in Russia. NOT approved in US, EU, or UK.WADA: Not prohibited |
| ▶ | SemaxSemax | D | Cognitive enhancement, neuroprotection (Russia/Ukraine approved). Not approved in Western markets | Approved in Russia. NOT approved in US, EU, or UK.WADA: Not prohibited |
Endocrine Peptides
| Peptide (Brand Names) | Evidence | Indication | Regulatory Status |
|---|
| ▶ | Kisspeptin-10Kp-10 | C | Investigational: reproductive endocrinology, LH/FSH stimulation, emerging sexual function research | Not FDA-approved. FDA compounding risk flagged.WADA: Not prohibited |
Repair & Regenerative Peptides
| Peptide (Brand Names) | Evidence | Indication | Regulatory Status |
|---|
| ▶ | BPC-157Body Protection Compound-157, PL-14736 | E | Investigational: GI mucosal healing, tendon/ligament repair, wound healing. Human evidence sparse | Not FDA-approved. Bulk substance with potential significant safety risks.WADA: Not prohibited |
| ▶ | TB-500TB-500 (LKKTETQ fragment) | E | Investigational: tissue repair, wound healing. NOT full-length Thymosin β4 | Not FDA-approved. Bulk substance with potential significant safety risks.WADA: Not prohibited |
| ▶ | LL-37LL-37, Human cathelicidin | C | Investigational: wound healing (venous leg ulcers), innate immune modulation | Not FDA-approved. FDA compounding risk flagged.WADA: Not prohibited |
Immune, Longevity & Other Peptides
| Peptide (Brand Names) | Evidence | Indication | Regulatory Status |
|---|
| ▶ | Thymosin Alpha-1Zadaxin, Thymalfasin | C | Hepatitis B/C, cancer adjunct, immune deficiency (approved China, Italy, 35+ countries). Not FDA-approved | Approved in China, Italy (Zadaxin), 35+ countries. NOT FDA-approved.WADA: Not prohibited |
| ▶ | GHK-CuCopper tripeptide, copper peptide | D | Cosmetic/dermatologic: skin aging, wound healing (topical). Injectable claims NOT validated | Not FDA-approved as a drug. FDA compounding risk flagged for injectable forms.WADA: Not prohibited |
| ▶ | EpithalonEpitalon, Epithalone, AEDG | E | Investigational: longevity, circadian rhythm restoration, telomere biology. No robust human clinical evidence | Not approved anywhere. Research use only. FDA compounding risk flagged.WADA: Not prohibited |
| ▶ | MOTS-cMOTS-c | E | Investigational: metabolic disease, aging, exercise performance. No human RCTs | Not approved. Research compound. FDA compounding risk flagged.WADA: Not prohibited |
